Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Crestwood, US
Size (employees)
32 (est)
Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, US
Report incorrect company information

Key People/Management at Apellis Pharmaceuticals

Cedric Francois

Cedric Francois

President and CEO
Mike Yeadon

Mike Yeadon

Chief Scientific Officer
Pascal Deschatelets

Pascal Deschatelets

Founder & Chief Operating Officer

Apellis Pharmaceuticals Office Locations

Apellis Pharmaceuticals has an office in Crestwood, San Francisco, Cambridge and Waltham
Crestwood, US (HQ)
6400 Westwind Way
Cambridge, US
1218 Massachusetts Ave
San Francisco, US
300 41 Grant Ave
Waltham, US
200 5th Ave
Show all (4)
Report incorrect company information

Apellis Pharmaceuticals Financials and Metrics

Apellis Pharmaceuticals Financials


EBIT (FY, 2017)

(50.8 m)

Cash (5-Mar-2018)

175.6 m
USDFY, 2017


175.6 m

Current Assets

182 m

Total Assets

182.1 m

Accounts Payable

3.7 m
USDFY, 2017

Net Income

(51 m)

Accounts Payable

932.3 k

Cash From Operating Activities

(46.6 m)

Cash From Financing Activities

197.4 m
USDY, 2017

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information